DNB Markets - Episurf Medical: Q3 report a non-event
The company reported its Q3 earnings (loss) on 29 October, but the key information was already known (released with the capital raise in mid-October), so the report was a non-event. We still like the progress being made, with a broadening of the product pipeline, more clinical documentation being published, and now also a more solid financial position. We reiterate our fair value of SEK3.5–9.5.Q3 earnings pre-announced earlier in October. With its refinancing in mid-October, the company pre-announced Q3 earnings (loss), so Friday’s Q3 report was somewhat of a non-event. As previously